National Bleeding Disorders Foundation/X
Aug 31, 2025, 09:45
Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
National Bleeding Disorders Foundation (NBDF) shared on X:
”A new forum piece in Research and Practice in Thrombosis and Haemostasis explores the complex factors at play, from long-term efficacy and safety questions to cost, access, and patient decision-making.
Read the full open-access article.”
A recent RPTH forum article examines why the uptake of hemophilia gene therapy remains modest, citing concerns over long-term efficacy and safety, high costs, access barriers, and competition from effective non-factor therapies.
Latest news in the field of bleeding disorders featured in Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis